Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (181-190 of 273) with videos related to

Pageof 28
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.
JAMA Network Open|March 26, 2025
Quantitative Bias Analysis for Single-Arm Trials With External Control ArmsAlind Gupta, Grace Hsu, Seamus Kent, et al.
Lung Cancer Management|June 4, 2021
HER3 expression and MEK activation in non-small-cell lung carcinomaThubeena Manickavasagar, Wei Yuan, Suzanne Carreira, et al.
Frontiers in Oncology|February 7, 2024
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus reportMyriam Mirza, Aseem Shrivastava, Cecile Matthews, et al.
Histopathology|August 19, 2020
Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 casesWei-Chin Chang, Yu Zhi Zhang, Janina L Wolf, et al.
The Lancet Regional Health. Europe|March 13, 2024
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspectiveIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating <i>EGFR</i> Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.
BMJ Open Respiratory Research|June 9, 2026
Observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE): study protocolSindhu Bhaarrati Naidu, Gabrielle Guvensen, Honghan Wu, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2026
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspectiveVéronique Hofman, Guylène Rignol, Baharia Mograbi, et al.
Pageof 28

Showing results (181-190 of 273) with videos related to

Sort By:
Pageof 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.
JAMA Network Open|March 26, 2025
Quantitative Bias Analysis for Single-Arm Trials With External Control ArmsAlind Gupta, Grace Hsu, Seamus Kent, et al.
Lung Cancer Management|June 4, 2021
HER3 expression and MEK activation in non-small-cell lung carcinomaThubeena Manickavasagar, Wei Yuan, Suzanne Carreira, et al.
Frontiers in Oncology|February 7, 2024
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus reportMyriam Mirza, Aseem Shrivastava, Cecile Matthews, et al.
Histopathology|August 19, 2020
Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 casesWei-Chin Chang, Yu Zhi Zhang, Janina L Wolf, et al.
The Lancet Regional Health. Europe|March 13, 2024
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspectiveIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating <i>EGFR</i> Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.
BMJ Open Respiratory Research|June 9, 2026
Observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE): study protocolSindhu Bhaarrati Naidu, Gabrielle Guvensen, Honghan Wu, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2026
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspectiveVéronique Hofman, Guylène Rignol, Baharia Mograbi, et al.
Pageof 28